Central Nervous System Therapeutics Market
Central Nervous System Therapeutics Market Forecasts to 2030 - Global Analysis By Disease (Neurovascular Diseases, Mental Health, Degenerative Disorders, CNS Trauma, CNS Cancer, Infectious Diseases and Other Diseases), Drug Classes (Antidepressant, Analgesics, Anesthetics, Anti-Parkinson Drugs, Anti-Epileptics, Decarboxylase Inhibitors, Dopamine Agonists, Immunomodulatory Drug and Other Drug Classes ),Distribution Channel, Age Group and By Geography
|
Years Covered |
2021-2030 |
|
Estimated Year Value (2023) |
US $104.7 BN |
|
Projected Year Value (2030) |
US $182.12 BN |
|
CAGR (2023 - 2030) |
8.2% |
|
Regions Covered |
North America, Europe, Asia Pacific, South America, and Middle East & Africa |
|
Countries Covered |
US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa |
|
Largest Market |
North America |
|
Highest Growing Market |
Asia Pacific |
According to Stratistics MRC, the Global Central Nervous System Therapeutics Market is accounted for $104.7 billion in 2023 and is expected to reach $182.12 billion by 2030 growing at a CAGR of 8.2% during the forecast period. Central Nervous System (CNS) therapeutics are drugs that are used to treat diseases of the brain and spinal cord. They are a broad class of drugs that include many different types, each with its own specific mechanism of action. CNS therapeutics is used to treat a wide range of neurological and psychiatric conditions. Some common CNS therapeutics include antidepressants, which are used to treat depression and certain anxiety disorders, anti-epileptics, which are used to control seizures and are essential in the treatment of epilepsy, antipsychotics, which are used to manage psychotic disorders like schizophrenia and bipolar disorders, etc.
According to the World Health Organization (WHO) report, more than 55 million people have dementia worldwide, and nearly 10 million new cases are reported yearly.
Market Dynamics:
Driver:
Development of innovative drug delivery systems
Innovative drug delivery systems have emerged as a result of the development of new therapies for the treatment of illnesses of the central nervous system. The creation of these cutting-edge drug delivery systems is anticipated to accelerate the expansion of the market for the central nervous system. The adverse effects of modern treatments and medication delivery technologies are minimal or nonexistent. Additionally, the demand for therapies for the central nervous system is anticipated to be significantly impacted by the population's growing knowledge of neurodegenerative diseases and mental health.
Restraint:
High costs of CNS drugs
CNS medications require considerable research and development, which is expensive for CNS drug makers and raises the final product's cost. Longer approval durations further raise the risk of investing; thus, CNS drug suppliers price their goods high to recover their expenses and maintain profitability. However, these issues all have a negative impact on patients who acquire these CNS medications and excessive prices even prevent the sale of CNS medications in areas with little spending potential. These elements are significant barriers to market expansion.
Opportunity:
Public awareness
Public awareness about mental health and neurological disorders has grown significantly. The need for CNS medications has increased as a result of the early identification and treatment made possible by this enhanced awareness. Additionally, governments and healthcare institutions are becoming more aware of the significance of mental health, which has improved healthcare infrastructure and led to better healthcare regulations that promote the creation and distribution of CNS medications. Therefore, it leads to market growth.
Threat:
Drug resistance
The therapeutic market for the central nervous system (CNS) is concerned by the threat of drug resistance. Patients gradually become less receptive to previously effective drugs in this syndrome, which is frequently seen in disorders like epilepsy. It not only lowers therapy effectiveness but also forces the creation of new treatments. Drug resistance makes treating CNS illnesses more difficult, and researchers must constantly come up with new solutions to this problem. Patients who have resistance can have trouble locating effective medications, which could lead to insufficient illness control and the requirement for more intrusive measures. These factors hinder market demand.
Covid-19 Impact
The market for treatments for the central nervous system was significantly impacted by the COVID-19 pandemic. Even the number of people receiving treatment for CNS illnesses and the number of new CNS drugs approved has decreased as a result of the epidemic. Additionally, the pandemic interfered with ongoing CNS therapeutic research and clinical trials. Due to limitations on patient recruitment, restricted access to medical facilities, and the priority given to COVID-19 research, several trials had to be stopped or put on hold. New CNS medicines' development and regulatory approval were subsequently delayed as a result.
The antidepressant segment is expected to be the largest during the forecast period.
The antidepressant segment is estimated to hold the largest share. Increased knowledge and identification of mental health conditions like depression and anxiety, better access to mental health services, and the usefulness and efficacy of antidepressants in treating a variety of CNS illnesses are all contributing factors to the rising prevalence of mental health problems like these. Antidepressant medication development has advanced significantly in the pharmaceutical sector. Innovative types of antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), serotonin-nor epinephrine reuptake inhibitors (SNRIs), and atypical antidepressants, offer higher efficacy and tolerability profiles as compared to earlier generations of medications.
The paediatric segment is expected to have the highest CAGR during the forecast period.
The paediatric segment is anticipated to have lucrative growth during the forecast period. The Paediatric segment of the Nervous System Therapeutics Market is dedicated to therapeutic solutions and regimens created especially for children with neurological illnesses and disorders. These include hereditary illnesses, epilepsy, cerebral palsy, ADHD, and autism spectrum disorders. The category focuses on the creation and distribution of paediatric medication formulations, kid-friendly medical gadgets, and age-appropriate diagnostic equipment. Growing awareness of early intervention, the frequency of neurological illnesses in children, and developments in paediatric neurology research and therapies are all driving factors in the market.
Region with largest share:
North America commanded the largest market share during the extrapolated period owing to the growth of technology in the pharmaceutical sector that helps in new drug developments, increasing product launches, the rising burden of central nervous system diseases, and the rising level of research and developments in the countries like the United States and Canada. Additionally, the prevalence of neurological disorders is rising, which increases funding and support for research initiatives that provide cutting-edge therapies and could accelerate the market's expansion.
Region with highest CAGR:
Asia Pacific is expected to witness profitable growth over the projection period. The major market drivers are the growing government investments in enhancing the healthcare infrastructure and the prevalence of numerous patients with unmet medical needs. The non-profit organisations are doing an outstanding job of raising awareness about mental health and CNS therapeutics while also offering free treatments for CNS illnesses.
Key players in the market
Some of the key players in the Central Nervous System Therapeutics Market include Biogen, Astra Zeneca, Eli Lilly and Company, Merck & Co., Johnson & Johnson Services, Inc., Otsuka Pharmaceutical Co., Ltd., Hand Pharma, Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Shire PLC, GlaxoSmithKline PLC and Pfizer, Inc.
Key Developments:
In February 2023, Sage Therapeutics, Inc. and Biogen Inc received acceptance from the United States FDA for a New Drug Application (NDA) application for zuranolone in the treatment of the major depressive disorder (MDD) and postpartum depression (PPD).
In January 2023, Biogen Inc. received Accelerated Approval from United States FDA for lecanemab-irmb (LEQEMBI) 100 mg/mL injection for intravenous use, a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta (A?) for the treatment of Alzheimer's disease (AD).
Diseases Covered:
• Neurovascular Diseases
• Mental Health
• Degenerative Disorders
• CNS Trauma
• CNS Cancer
• Infectious Diseases
• Other Diseases
Drug Classes Covered:
• Antidepressant
• Analgesics
• Anesthetics
• Anti-Parkinson Drugs
• Anti-Epileptics
• Decarboxylase Inhibitors
• Dopamine Agonists
• Immunomodulatory Drug
• Other Drug Classes
Distribution Channels Covered:
• Retail Pharmacy
• Hospital-Based Pharmacies
• Online Pharmacy
Age Groups Covered:
• Pediatric
• Geriatric
• Adults
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Emerging Markets
3.7 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Central Nervous System Therapeutics Market, By Disease
5.1 Introduction
5.2 Neurovascular Diseases
5.3 Mental Health
5.3.1 Anxiety Disorders
5.3.2 Epilepsy
5.3.3 Mood Disorders
5.3.4 Psychotic Disorders
5.4 Degenerative Disorders
5.4.1 Parkinson’s Disease
5.4.2 Alzheimer's Disease
5.4.3 Huntington’s Disease
5.4.4 Multiple Sclerosis
5.4.5 Amyotrophic Lateral Sclerosis
5.5 CNS Trauma
5.6 CNS Cancer
5.7 Infectious Diseases
5.8 Other Diseases
6 Global Central Nervous System Therapeutics Market, By Drug Class
6.1 Introduction
6.2 Antidepressant
6.3 Analgesics
6.4 Anesthetics
6.5 Anti-Parkinson Drugs
6.6 Anti-Epileptics
6.7 Decarboxylase Inhibitors
6.8 Dopamine Agonists
6.9 Immunomodulatory Drug
6.10 Other Drug Classes
7 Global Central Nervous System Therapeutics Market, By Distribution Channel
7.1 Introduction
7.2 Retail Pharmacy
7.3 Hospital-Based Pharmacies
7.4 Online Pharmacy
8 Global Central Nervous System Therapeutics Market, By Age Group
8.1 Introduction
8.2 Pediatric
8.3 Geriatric
8.4 Adults
9 Global Central Nervous System Therapeutics Market, By Geography
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.2.3 Mexico
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 Italy
9.3.4 France
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 New Zealand
9.4.6 South Korea
9.4.7 Rest of Asia Pacific
9.5 South America
9.5.1 Argentina
9.5.2 Brazil
9.5.3 Chile
9.5.4 Rest of South America
9.6 Middle East & Africa
9.6.1 Saudi Arabia
9.6.2 UAE
9.6.3 Qatar
9.6.4 South Africa
9.6.5 Rest of Middle East & Africa
10 Key Developments
10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies
11 Company Profiling
11.1 Biogen
11.2 Astra Zeneca
11.3 Eli Lilly and Company
11.4 Merck & Co.
11.5 Johnson & Johnson Services, Inc.
11.6 Otsuka Pharmaceutical Co., Ltd.
11.7 Hand Pharma, Inc.
11.8 Novartis AG
11.9 Takeda Pharmaceutical Company Limited
11.10 Teva Pharmaceutical Industries Ltd.
11.11 Shire PLC
11.12 GlaxoSmithKline PLC
11.13 Pfizer, Inc.
List of Tables
1 Global Central Nervous System Therapeutics Market Outlook, By Region (2021-2030) ($MN)
2 Global Central Nervous System Therapeutics Market Outlook, By Disease (2021-2030) ($MN)
3 Global Central Nervous System Therapeutics Market Outlook, By Neurovascular Diseases (2021-2030) ($MN)
4 Global Central Nervous System Therapeutics Market Outlook, By Mental Health (2021-2030) ($MN)
5 Global Central Nervous System Therapeutics Market Outlook, By Anxiety Disorders (2021-2030) ($MN)
6 Global Central Nervous System Therapeutics Market Outlook, By Epilepsy (2021-2030) ($MN)
7 Global Central Nervous System Therapeutics Market Outlook, By Mood Disorders (2021-2030) ($MN)
8 Global Central Nervous System Therapeutics Market Outlook, By Psychotic Disorders (2021-2030) ($MN)
9 Global Central Nervous System Therapeutics Market Outlook, By Degenerative Disorders (2021-2030) ($MN)
10 Global Central Nervous System Therapeutics Market Outlook, By Parkinson’s Disease (2021-2030) ($MN)
11 Global Central Nervous System Therapeutics Market Outlook, By Alzheimer's Disease (2021-2030) ($MN)
12 Global Central Nervous System Therapeutics Market Outlook, By Huntington’s Disease (2021-2030) ($MN)
13 Global Central Nervous System Therapeutics Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
14 Global Central Nervous System Therapeutics Market Outlook, By Amyotrophic Lateral Sclerosis (2021-2030) ($MN)
15 Global Central Nervous System Therapeutics Market Outlook, By CNS Trauma (2021-2030) ($MN)
16 Global Central Nervous System Therapeutics Market Outlook, By CNS Cancer (2021-2030) ($MN)
17 Global Central Nervous System Therapeutics Market Outlook, By Infectious Diseases (2021-2030) ($MN)
18 Global Central Nervous System Therapeutics Market Outlook, By Other Diseases (2021-2030) ($MN)
19 Global Central Nervous System Therapeutics Market Outlook, By Drug Class (2021-2030) ($MN)
20 Global Central Nervous System Therapeutics Market Outlook, By Antidepressant (2021-2030) ($MN)
21 Global Central Nervous System Therapeutics Market Outlook, By Analgesics (2021-2030) ($MN)
22 Global Central Nervous System Therapeutics Market Outlook, By Anesthetics (2021-2030) ($MN)
23 Global Central Nervous System Therapeutics Market Outlook, By Anti-Parkinson Drugs (2021-2030) ($MN)
24 Global Central Nervous System Therapeutics Market Outlook, By Anti-Epileptics (2021-2030) ($MN)
25 Global Central Nervous System Therapeutics Market Outlook, By Decarboxylase Inhibitors (2021-2030) ($MN)
26 Global Central Nervous System Therapeutics Market Outlook, By Dopamine Agonists (2021-2030) ($MN)
27 Global Central Nervous System Therapeutics Market Outlook, By Immunomodulatory Drug (2021-2030) ($MN)
28 Global Central Nervous System Therapeutics Market Outlook, By Other Drug Classes (2021-2030) ($MN)
29 Global Central Nervous System Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
30 Global Central Nervous System Therapeutics Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
31 Global Central Nervous System Therapeutics Market Outlook, By Hospital-Based Pharmacies (2021-2030) ($MN)
32 Global Central Nervous System Therapeutics Market Outlook, By Online Pharmacy (2021-2030) ($MN)
33 Global Central Nervous System Therapeutics Market Outlook, By Age Group (2021-2030) ($MN)
34 Global Central Nervous System Therapeutics Market Outlook, By Pediatric (2021-2030) ($MN)
35 Global Central Nervous System Therapeutics Market Outlook, By Geriatric (2021-2030) ($MN)
36 Global Central Nervous System Therapeutics Market Outlook, By Adults (2021-2030) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
